<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230907021034&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230907021034&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 07 Sep 2023 06:10:36 +0000</lastbuilddate>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Hot topics in congenital heart disease: tetralogy of Fallot, Ross operation, immunodeficiency, cardiac arrest, and end-stage heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37673665/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 7;44(34):3201-3204. doi: 10.1093/eurheartj/ehad549.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37673665/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37673665</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad549>10.1093/eurheartj/ehad549</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37673665</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hot topics in congenital heart disease: tetralogy of Fallot, Ross operation, immunodeficiency, cardiac arrest, and end-stage heart failure</dc:title>
<dc:identifier>pmid:37673665</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad549</dc:identifier>
</item>
<item>
<title>Ventricular Arrhythmias in Adults With Congenital Heart Disease, Part II: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37673513/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>There are marked variations in the incidence of sudden cardiac death (SCD) and in the substrates for ventricular arrhythmias (VAs) across the gamut of congenital heart defects. In this 2-part review, patients with higher-risk forms of congenital heart disease (CHD) were conceptually categorized into those with discrete anatomic isthmuses for macro-reentrant ventricular tachycardia (VT) (Group A) and those with more diffuse or less well-defined substrates (Group B) that include patchy or...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 12;82(11):1121-1130. doi: 10.1016/j.jacc.2023.06.036.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There are marked variations in the incidence of sudden cardiac death (SCD) and in the substrates for ventricular arrhythmias (VAs) across the gamut of congenital heart defects. In this 2-part review, patients with higher-risk forms of congenital heart disease (CHD) were conceptually categorized into those with discrete anatomic isthmuses for macro-reentrant ventricular tachycardia (VT) (Group A) and those with more diffuse or less well-defined substrates (Group B) that include patchy or extensive myocardial fibrosis. The latter category encompasses CHD lesions such as Ebstein anomaly, transposition of the great arteries with a systemic right ventricle (RV), and congenital aortic stenosis. For Group B patients, polymorphic VT and ventricular fibrillation account for a higher proportion of VA. The prognostic value of programmed ventricular stimulation is less well established, and catheter ablation plays a less prominent role. As cardiomyopathies evolve over time, pathophysiological mechanisms for VA among Groups A and B become increasingly blurred.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37673513/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37673513</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.036>10.1016/j.jacc.2023.06.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37673513</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Francis Bessière</dc:creator>
<dc:creator>Victor Waldmann</dc:creator>
<dc:creator>Nicolas Combes</dc:creator>
<dc:creator>Olivier Metton</dc:creator>
<dc:creator>Nabil Dib</dc:creator>
<dc:creator>Blandine Mondésert</dc:creator>
<dc:creator>Edward O'Leary</dc:creator>
<dc:creator>Elizabeth De Witt</dc:creator>
<dc:creator>Chrystalle Katte Carreon</dc:creator>
<dc:creator>Stephen P Sanders</dc:creator>
<dc:creator>Jeremy P Moore</dc:creator>
<dc:creator>John Triedman</dc:creator>
<dc:creator>Paul Khairy</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ventricular Arrhythmias in Adults With Congenital Heart Disease, Part II: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37673513</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.036</dc:identifier>
</item>
<item>
<title>Ventricular Arrhythmias in Adults With Congenital Heart Disease, Part I: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37673512/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>Patients with congenital heart disease associated with a higher risk for ventricular arrhythmias (VA) and sudden cardiac death (SCD) can be divided conceptually into those with discrete mechanisms for reentrant monomorphic ventricular tachycardia (VT) (Group A) and those with more diffuse substrates (Group B). Part I of this review addresses Group A lesions, which predominantly consist of tetralogy of Fallot and related variants. Well-defined anatomic isthmuses for reentrant monomorphic VT are...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 12;82(11):1108-1120. doi: 10.1016/j.jacc.2023.06.034.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Patients with congenital heart disease associated with a higher risk for ventricular arrhythmias (VA) and sudden cardiac death (SCD) can be divided conceptually into those with discrete mechanisms for reentrant monomorphic ventricular tachycardia (VT) (Group A) and those with more diffuse substrates (Group B). Part I of this review addresses Group A lesions, which predominantly consist of tetralogy of Fallot and related variants. Well-defined anatomic isthmuses for reentrant monomorphic VT are interposed between surgical scars and the pulmonary or tricuspid annulus. The most commonly implicated critical isthmus for VT is the conal septum that divides subpulmonary from subaortic outlets. Programmed ventricular stimulation can be helpful in risk stratification. Although catheter ablation is not generally considered an alternative to the implantable cardioverter-defibrillator (ICD) for prevention of SCD, emerging data suggest that there is a subset of carefully selected patients who may not require ICDs after successful monomorphic VT ablation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37673512/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37673512</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.034>10.1016/j.jacc.2023.06.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37673512</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Francis Bessière</dc:creator>
<dc:creator>Victor Waldmann</dc:creator>
<dc:creator>Nicolas Combes</dc:creator>
<dc:creator>Olivier Metton</dc:creator>
<dc:creator>Nabil Dib</dc:creator>
<dc:creator>Blandine Mondésert</dc:creator>
<dc:creator>Edward O'Leary</dc:creator>
<dc:creator>Elizabeth De Witt</dc:creator>
<dc:creator>Chrystalle Katte Carreon</dc:creator>
<dc:creator>Stephen P Sanders</dc:creator>
<dc:creator>Jeremy P Moore</dc:creator>
<dc:creator>John Triedman</dc:creator>
<dc:creator>Paul Khairy</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ventricular Arrhythmias in Adults With Congenital Heart Disease, Part I: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37673512</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.034</dc:identifier>
</item>
<item>
<title>Vasovagal Responses to Human Monomorphic Ventricular Tachycardia: Atropine to the Rescue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37673511/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 12;82(11):1106-1107. doi: 10.1016/j.jacc.2023.06.035.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37673511/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37673511</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.035>10.1016/j.jacc.2023.06.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37673511</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Andre d'Avila</dc:creator>
<dc:creator>Robert N D'Angelo</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Vasovagal Responses to Human Monomorphic Ventricular Tachycardia: Atropine to the Rescue</dc:title>
<dc:identifier>pmid:37673511</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.035</dc:identifier>
</item>
<item>
<title>Vasovagal Responses to Human Monomorphic Ventricular Tachycardia: Hemodynamic Implications From Sinus Rate Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37673510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Nearly one-half of VT episodes are associated with failure to augment SR, indicative of an under-recognized pathophysiological vasovagal response to VT. Inappropriate SR responses were more predictive of hemodynamic instability than VT rate and ejection fraction. Vagolytic therapy may be a novel method to augment blood pressure during VT.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 12;82(11):1096-1105. doi: 10.1016/j.jacc.2023.06.033.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Factors determining hemodynamic stability during human ventricular tachycardia (VT) are incompletely understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purposes of this study were to characterize sinus rate (SR) responses during monomorphic VT in association with hemodynamic stability and to prospectively assess the effects of vagolytic therapy on VT tolerance.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This is a retrospective analysis of patients undergoing scar-related VT ablation. Vasovagal responses were evaluated by analyzing sinus cycle length before VT induction and during VT. SR responses were classified into 3 groups: increasing (≥5 beats/min, sympathetic), decreasing (≥5 beats/min, vagal), and unchanged, with the latter 2 categorized as inappropriate SR. In a prospective cohort (n = 30) that exhibited a failure to increase SR, atropine was administered to improve hemodynamic tolerance to VT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In 150 patients, 261 VT episodes were analyzed (29% untolerated, 71% tolerated) with median VT duration 1.6 minutes. A total of 52% of VT episodes were associated with a sympathetic response, 31% had unchanged SR, and 17% of VTs exhibited a vagal response. A significantly higher prevalence of inappropriate SR responses was observed during untolerated VT (sustained VT requiring cardioversion within 150 seconds) compared with tolerated VT (84% vs 34%; P &lt; 0.001). Untolerated VT was significantly different between groups: 9% (sympathetic), 82% (vagal), and 32% (unchanged) (P &lt; 0.001). Atropine administration improved hemodynamic tolerance to VT in 70%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Nearly one-half of VT episodes are associated with failure to augment SR, indicative of an under-recognized pathophysiological vasovagal response to VT. Inappropriate SR responses were more predictive of hemodynamic instability than VT rate and ejection fraction. Vagolytic therapy may be a novel method to augment blood pressure during VT.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37673510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37673510</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.033>10.1016/j.jacc.2023.06.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37673510</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Margarida Pujol-Lopez</dc:creator>
<dc:creator>Jeanne Du Fay de Lavallaz</dc:creator>
<dc:creator>Pooja Rangan</dc:creator>
<dc:creator>Andrew Beaser</dc:creator>
<dc:creator>Zaid Aziz</dc:creator>
<dc:creator>Gaurav A Upadhyay</dc:creator>
<dc:creator>Hemal Nayak</dc:creator>
<dc:creator>J Peter Weiss</dc:creator>
<dc:creator>Michael Zawaneh</dc:creator>
<dc:creator>Rong Bai</dc:creator>
<dc:creator>Wilber Su</dc:creator>
<dc:creator>Roderick Tung</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Vasovagal Responses to Human Monomorphic Ventricular Tachycardia: Hemodynamic Implications From Sinus Rate Analysis</dc:title>
<dc:identifier>pmid:37673510</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.033</dc:identifier>
</item>
<item>
<title>Lifetime Aortic Management in Marfan Syndrome: Puzzle Pieces and Rare Diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37673509/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 12;82(11):1077-1079. doi: 10.1016/j.jacc.2023.07.004.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37673509/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37673509</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.004>10.1016/j.jacc.2023.07.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37673509</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Joseph S Coselli</dc:creator>
<dc:creator>Lauren M Barron</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lifetime Aortic Management in Marfan Syndrome: Puzzle Pieces and Rare Diseases</dc:title>
<dc:identifier>pmid:37673509</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.004</dc:identifier>
</item>
<item>
<title>Cardiovascular Events After Aortic Root Repair in Patients With Marfan Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37673508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Aortic valve sparing operations provide stable aortic valve function and low rates of valve-related complications during the first 2 decades of follow-up but aortic dissections remain problematic in patients with MS.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 12;82(11):1068-1076. doi: 10.1016/j.jacc.2023.06.032.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The usefulness of aortic valve sparing operations to treat aortic root aneurysm in patients with Marfan syndrome (MS) remains controversial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to evaluate the occurrence of cardiovascular events in patients with MS who have undergone valve-preserving aortic root replacement.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with MS who had aortic valve sparing operations (reimplantation of the aortic valve or remodeling of the aortic root) from 1988 through 2019 were followed prospectively for a median of 14 years. Pertinent data from clinical, echocardiographic, computed tomography, and magnetic resonance images of the aorta were collected and analyzed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: There were 189 patients whose mean age was 36 years, and 67% were men. Ten patients presented with acute type A dissection and 29 had mitral regurgitation. There were 52 patients at risk at 20 years. Mortality rate at 20 years was 21.5% (95% CI: 14.7%-30.8%); advancing age and preoperative aortic dissections were associated with increased risk of death by multivariable analysis. At 20 years, the cumulative incidence of moderate or severe aortic insufficiency was 14.5% (95% CI: 9.5%-22.0%), reoperation on the aortic valve was 7.5% (95% CI: 3.9%-14.7%), and new distal aortic dissections was 19.9% (95% CI: 13.9%-28.5%). Remodeling of aortic root was associated with greater risk of developing aortic insufficiency and aortic valve reoperation than reimplantation of the aortic valve.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Aortic valve sparing operations provide stable aortic valve function and low rates of valve-related complications during the first 2 decades of follow-up but aortic dissections remain problematic in patients with MS.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37673508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37673508</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.032>10.1016/j.jacc.2023.06.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37673508</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Tirone E David</dc:creator>
<dc:creator>Joy Park</dc:creator>
<dc:creator>Mark Tatangelo</dc:creator>
<dc:creator>Chun-Po Steve Fan</dc:creator>
<dc:creator>Maral Ouzounian</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiovascular Events After Aortic Root Repair in Patients With Marfan Syndrome</dc:title>
<dc:identifier>pmid:37673508</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.032</dc:identifier>
</item>
<item>
<title>The Winding Path Toward Understanding Clinically Isolated Aortitis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37673507/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 12;82(11):1065-1067. doi: 10.1016/j.jacc.2023.07.005.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37673507/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37673507</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.005>10.1016/j.jacc.2023.07.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37673507</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>James R Stone</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Winding Path Toward Understanding Clinically Isolated Aortitis</dc:title>
<dc:identifier>pmid:37673507</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.005</dc:identifier>
</item>
<item>
<title>Long-Term Outcome and Prognosis of Noninfectious Thoracic Aortitis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37673506/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This multicenter study shows that 82% of noninfectious surgical thoracic aortitis patients will experience a vascular complication within 10 years. We pointed out specific characteristics that identified those at highest risk for subsequent vascular complications and second vascular procedures.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 12;82(11):1053-1064. doi: 10.1016/j.jacc.2023.06.031.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Aortitis is a group of disorders characterized by the inflammation of the aorta. The large-vessel vasculitides are the most common causes of aortitis. Aortitis long-term outcomes are not well known.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to assess the long-term outcome and prognosis of noninfectious surgical thoracic aortitis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a retrospective multicenter study of 5,666 patients with thoracic aorta surgery including 217 (3.8%) with noninfectious thoracic aortitis (118 clinically isolated aortitis, 57 giant cells arteritis, 21 Takayasu arteritis, and 21 with various systemic autoimmune disorders). Factors associated with vascular complications and a second vascular procedure were assessed by multivariable analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Indications for aortic surgery were asymptomatic aneurysm with a critical size (n = 152 [70%]), aortic dissection (n = 28 [13%]), and symptomatic aortic aneurysm (n = 30 [14%]). The 10-year cumulative incidence of vascular complication and second vascular procedure was 82.1% (95% CI: 67.6%-90.6%), and 42.6% (95% CI: 28.4%-56.1%), respectively. Aortic arch aortitis (HR: 2.08; 95% CI: 1.26-3.44; P = 0.005) was independently associated with vascular complications. Descending thoracic aortitis (HR: 2.35; 95% CI: 1.11-4.96; P = 0.031) and aortic dissection (HR: 3.08; 95% CI: 1.61-5.90; P = 0.002) were independently associated with a second vascular procedure, while treatment with statins after aortitis diagnosis (HR: 0.47; 95% CI: 0.24-0.90; P = 0.028) decreased it. After a median follow-up of 3.9 years, 19 (16.1%) clinically isolated aortitis patients developed features of a systemic inflammatory disease and 35 (16%) patients had died.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This multicenter study shows that 82% of noninfectious surgical thoracic aortitis patients will experience a vascular complication within 10 years. We pointed out specific characteristics that identified those at highest risk for subsequent vascular complications and second vascular procedures.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37673506/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37673506</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.031>10.1016/j.jacc.2023.06.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37673506</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Olivier Espitia</dc:creator>
<dc:creator>Patrick Bruneval</dc:creator>
<dc:creator>Morgane Assaraf</dc:creator>
<dc:creator>Jacques Pouchot</dc:creator>
<dc:creator>Eric Liozon</dc:creator>
<dc:creator>Hubert de Boysson</dc:creator>
<dc:creator>Julien Gaudric</dc:creator>
<dc:creator>Laurent Chiche</dc:creator>
<dc:creator>Paul Achouh</dc:creator>
<dc:creator>Jean-Christian Roussel</dc:creator>
<dc:creator>Sébastien Miranda</dc:creator>
<dc:creator>Tristan Mirault</dc:creator>
<dc:creator>Samia Boussouar</dc:creator>
<dc:creator>Alban Redheuil</dc:creator>
<dc:creator>Jean-Michel Serfaty</dc:creator>
<dc:creator>Antoine Bénichou</dc:creator>
<dc:creator>Christian Agard</dc:creator>
<dc:creator>Alexis F Guédon</dc:creator>
<dc:creator>Patrice Cacoub</dc:creator>
<dc:creator>François Paraf</dc:creator>
<dc:creator>Pierre-Jean Fouret</dc:creator>
<dc:creator>Claire Toquet</dc:creator>
<dc:creator>Lucie Biard</dc:creator>
<dc:creator>David Saadoun</dc:creator>
<dc:creator>French Study Group for Large Vessel Vasculitides (GEFA)</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Outcome and Prognosis of Noninfectious Thoracic Aortitis</dc:title>
<dc:identifier>pmid:37673506</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.031</dc:identifier>
</item>
<item>
<title>VA-ECMO does not increase survival in MI-related cardiogenic shock</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37674058/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 6. doi: 10.1038/s41569-023-00929-4. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37674058/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37674058</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00929-4>10.1038/s41569-023-00929-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37674058</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>VA-ECMO does not increase survival in MI-related cardiogenic shock</dc:title>
<dc:identifier>pmid:37674058</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00929-4</dc:identifier>
</item>
<item>
<title>Adult With Unrepaired Single-Ventricle Defect</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37672288/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 6. doi: 10.1001/jamacardio.2023.2748. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37672288/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37672288</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2748>10.1001/jamacardio.2023.2748</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37672288</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>David Gregg</dc:creator>
<dc:creator>Andrew D Vogel</dc:creator>
<dc:creator>Taufiek K Rajab</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Adult With Unrepaired Single-Ventricle Defect</dc:title>
<dc:identifier>pmid:37672288</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2748</dc:identifier>
</item>
<item>
<title>Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37672268/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In this exploratory cohort, valsartan was not proven to slow progression of subclinical HCM. Minimal changes in markers of cardiac remodeling were observed, although nearly one-fifth of patients developed clinically overt HCM. Transition to disease was associated with greater baseline interventricular septum thickness and LAVI. These findings highlight the importance of following sarcomere variant carriers longitudinally and the critical need to improve understanding...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 6. doi: 10.1001/jamacardio.2023.2808. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Valsartan has shown promise in attenuating cardiac remodeling in patients with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Genetic testing can identify individuals at risk of HCM in a subclinical stage who could benefit from therapies that prevent disease progression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To explore the potential for valsartan to modify disease development, and to characterize short-term phenotypic progression in subclinical HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The multicenter, double-blind, placebo-controlled Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) randomized clinical trial was conducted from April 2014 to July 2019 at 17 sites in 4 countries (Brazil, Canada, Denmark, and the US), with 2 years of follow-up. The prespecified exploratory VANISH cohort studied here included sarcomere variant carriers with subclinical HCM and early phenotypic manifestations (reduced E' velocity, electrocardiographic abnormalities, or an increased left ventricular [LV] wall thickness [LVWT] to cavity diameter ratio) but no LV hypertrophy (LVH). Data were analyzed between March and December 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Treatment with placebo or valsartan (80 mg/d for children weighing &lt;35 kg, 160 mg/d for children weighing ≥35 kg, or 320 mg/d for adults aged ≥18 years).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was a composite z score incorporating changes in 9 parameters of cardiac remodeling (LV cavity volume, LVWT, and LV mass; left atrial [LA] volume; E' velocity and S' velocity; and serum troponin and N-terminal prohormone of brain natriuretic peptide levels).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 34 participants, with a mean (SD) age of 16 (5) years (all were White). A total of 18 participants (8 female [44%] and 10 male [56%]) were randomized to valsartan and 16 (9 female [56%] and 7 male [44%]) were randomized to placebo. No statistically significant effects of valsartan on cardiac remodeling were detected (mean change in composite z score compared with placebo: -0.01 [95% CI, -0.29 to 0.26]; P = .92). Overall, 2-year phenotypic progression was modest, with only a mild increase in LA volume detected (increased by 3.5 mL/m2 [95% CI, 1.4-6.0 mL/m2]; P = .002). Nine participants (26%) had increased LVWT, including 6 (18%) who developed clinically overt HCM. Baseline LA volume index (LAVI; 35 vs 28 mL/m2; P = .01) and average interventricular septum thickness (8.5 vs 7.0 mm; P = .009) were higher in participants who developed HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this exploratory cohort, valsartan was not proven to slow progression of subclinical HCM. Minimal changes in markers of cardiac remodeling were observed, although nearly one-fifth of patients developed clinically overt HCM. Transition to disease was associated with greater baseline interventricular septum thickness and LAVI. These findings highlight the importance of following sarcomere variant carriers longitudinally and the critical need to improve understanding of factors that drive disease penetrance and progression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01912534.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37672268/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37672268</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2808>10.1001/jamacardio.2023.2808</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37672268</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Christoffer Rasmus Vissing</dc:creator>
<dc:creator>Anna Axelsson Raja</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Mark W Russell</dc:creator>
<dc:creator>Kenneth Zahka</dc:creator>
<dc:creator>Harry M Lever</dc:creator>
<dc:creator>Alexandre C Pereira</dc:creator>
<dc:creator>Steven D Colan</dc:creator>
<dc:creator>Renee Margossian</dc:creator>
<dc:creator>Anne M Murphy</dc:creator>
<dc:creator>Charles Canter</dc:creator>
<dc:creator>Richard G Bach</dc:creator>
<dc:creator>Matthew T Wheeler</dc:creator>
<dc:creator>Joseph W Rossano</dc:creator>
<dc:creator>Anjali T Owens</dc:creator>
<dc:creator>Lee Benson</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Amit R Patel</dc:creator>
<dc:creator>Ivan Wilmot</dc:creator>
<dc:creator>Philip Thrush</dc:creator>
<dc:creator>Jonathan H Soslow</dc:creator>
<dc:creator>Jason R Becker</dc:creator>
<dc:creator>Christine E Seidman</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Allison L Cirino</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Calum A MacRae</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>E John Orav</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:creator>Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37672268</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2808</dc:identifier>
</item>
<item>
<title>A Tribute to William C. Roberts, MD, 1932-2023</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37672267/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 6. doi: 10.1001/jamacardio.2023.2853. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37672267/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37672267</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2853>10.1001/jamacardio.2023.2853</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37672267</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>A Tribute to William C. Roberts, MD, 1932-2023</dc:title>
<dc:identifier>pmid:37672267</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2853</dc:identifier>
</item>
<item>
<title>Linking Kidney Vessel Scarring to Cardiovascular Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37672266/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 6. doi: 10.1001/jamacardio.2023.2752. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37672266/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37672266</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2752>10.1001/jamacardio.2023.2752</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37672266</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Thibaut d'Izarny-Gargas</dc:creator>
<dc:creator>Alexandre Karras</dc:creator>
<dc:creator>Jean-Paul Duong-Van-Huyen</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Linking Kidney Vessel Scarring to Cardiovascular Risk</dc:title>
<dc:identifier>pmid:37672266</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2752</dc:identifier>
</item>
<item>
<title>Insulin Resistance and N-Terminal Pro-B-Type Natriuretic Peptide Among Healthy Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37672260/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In a national sample of US adults, insulin resistance was inversely associated with NT-proBNP, even after rigorously accounting for multiple measures of fat mass and lean mass. These results suggest that the mechanisms linking NT-proBNP to insulin resistance are partially independent of excess adiposity and may be associated with hyperinsulinemia.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 6. doi: 10.1001/jamacardio.2023.2758. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: It is unclear to what extent insulin resistance is associated with N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the general population after accounting for body composition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To characterize the association of insulin resistance with NT-proBNP independently of measures of body composition in US adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: In a cross-sectional design, data on participants aged 20 years or older were obtained from the 1999-2004 National Health and Nutrition Examination Survey with measures of NT-pro-BNP, body mass index (BMI), and dual energy x-ray absorptiometry (DEXA)-derived measures of body composition (fat and lean masses). Linear and logistic regression was used to characterize the associations of measures of body mass and composition (BMI, waist circumference, fat mass, and lean mass) with NT-proBNP, adjusting for cardiovascular risk factors. Linear regression was used to characterize the associations of homeostasis model assessment of insulin resistance [HOMA-IR] and NT-proBNP after adjusting for cardiovascular risk factors and body composition measures. The quantitative insulin sensitivity check index [QUICKI], triglyceride-glucose index [TyG index], insulin to glucose ratio [IGR], fasting insulin, and homeostasis model assessment of β-cell function (HOMA-β) were also examined. Data for this study were analyzed from August 10, 2022, to June 30, 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Adjusted changes in NT-proBNP by insulin resistance levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 4038 adults without diabetes or cardiovascular disease were included (mean [SD] age, 44 years; 51.2% female; and 74.3% White). In sex-specific analyses, insulin resistance measures were inversely associated with NT-pro-BNP. After adjustment including cardiovascular risk factors, BMI, waist circumference, and DEXA-derived fat mass and lean mass, the percent change in NT-proBNP associated with an SD increase in HOMA-IR was -16.84% (95% CI, -21.23% to -12.21%) in women and -19.04% (95% CI, -24.14 to -13.59) in men. Similar associations were observed for other indices of insulin resistance, including QUICKI (women: 17.27; 95% CI, 10.92-23.99 vs men: 22.17; 95% CI, 15.27 to 29.48), TyG index women: -11.47; 95% CI, -16.12 to -6.57 vs men: -15.81; 95% CI, -20.40 to -10.95), IGR women: -15.15; 95% CI, -19.35 to -10.74 vs men: -16.61; 95% CI, -21.63 to -11.26), and fasting insulin (women: -16.32; 95% CI, -20.63 to -11.78 vs men: -18.22; 95% CI, -23.30 to -12.79), as well as HOMA-β (women: -10.71; 95% CI, -14.71 to -6.52 vs men: -11.72; 95% CI, -16.35 to -6.85).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In a national sample of US adults, insulin resistance was inversely associated with NT-proBNP, even after rigorously accounting for multiple measures of fat mass and lean mass. These results suggest that the mechanisms linking NT-proBNP to insulin resistance are partially independent of excess adiposity and may be associated with hyperinsulinemia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37672260/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37672260</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2758>10.1001/jamacardio.2023.2758</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37672260</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Justin B Echouffo-Tcheugui</dc:creator>
<dc:creator>Sui Zhang</dc:creator>
<dc:creator>John W McEvoy</dc:creator>
<dc:creator>Stephen P Juraschek</dc:creator>
<dc:creator>Michael Fang</dc:creator>
<dc:creator>Chiadi E Ndumele</dc:creator>
<dc:creator>Robert H Christenson</dc:creator>
<dc:creator>Elizabeth Selvin</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Insulin Resistance and N-Terminal Pro-B-Type Natriuretic Peptide Among Healthy Adults</dc:title>
<dc:identifier>pmid:37672260</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2758</dc:identifier>
</item>
<item>
<title>Linking Kidney Vessel Scarring to Cardiovascular Risk-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37672259/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 6. doi: 10.1001/jamacardio.2023.2755. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37672259/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37672259</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2755>10.1001/jamacardio.2023.2755</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37672259</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Leo Buckley</dc:creator>
<dc:creator>Ragnar Palsson</dc:creator>
<dc:creator>Sushrut S Waikar</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Linking Kidney Vessel Scarring to Cardiovascular Risk-Reply</dc:title>
<dc:identifier>pmid:37672259</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2755</dc:identifier>
</item>
<item>
<title>Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37671551/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Vericiguat use in the VICTORIA trial met criteria for intermediate value, but the incremental cost-effectiveness ratio estimates were sensitive to whether the analysis accounted for observed NT-proBNP treatment effect heterogeneity. The cost-effectiveness of vericiguat was driven by the projected incremental life expectancy among patients in the lowest 3 quartiles of NT-proBNP.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 6. doi: 10.1161/CIRCULATIONAHA.122.063602. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The VICTORIA trial (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) demonstrated that, in patients with high-risk heart failure, vericiguat reduced the primary composite outcome of cardiovascular death or heart failure hospitalization relative to placebo. The hazard ratio for all-cause mortality was 0.95 (95% CI, 0.84-1.07). In a prespecified analysis, treatment effects varied substantially as a function of baseline NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, with survival benefit for vericiguat in the lower NT-proBNP quartiles (hazard ratio, 0.82 [95% CI, 0.69-0.97]) and no benefit in the highest NT-proBNP quartile (hazard ratio, 1.14 [95% CI, 0.95-1.38]). An economic analysis was a major secondary objective of the VICTORIA research program.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Medical resource use data were collected for all VICTORIA patients (N=5050). Costs were estimated by applying externally derived US cost weights to resource use counts. Life expectancy was projected from patient-level empirical trial survival results with the use of age-based survival modeling methods. Quality-of-life adjustments were based on prospectively collected EQ-5D-based utilities. The primary outcome was the incremental cost-effectiveness ratio, comparing vericiguat with placebo, assessed from the US health care sector perspective over a lifetime horizon. Cost-effectiveness was estimated using the total VICTORIA cohort, both with and without interaction between treatment and baseline NT-proBNP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Life expectancy modeling results varied according to whether the observed heterogeneity of treatment effect by baseline NT-proBNP values was incorporated into the modeling. Including the interaction term, the vericiguat arm had an estimated quality-adjusted life expectancy of 4.56 quality-adjusted life-years (QALYs) compared with 4.13 QALYs for placebo (incremental discounted QALY, 0.43). Without the treatment heterogeneity/interaction term, vericiguat had 4.50 QALYs compared with 4.33 QALYs for placebo (incremental discounted QALY, 0.17). Incremental discounted costs (vericiguat minus placebo) were $28 546 with the treatment interaction and $20 948 without it. Corresponding incremental cost-effectiveness ratios were $66 509 per QALY allowing for treatment heterogeneity and $124 512 without heterogeneity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Vericiguat use in the VICTORIA trial met criteria for intermediate value, but the incremental cost-effectiveness ratio estimates were sensitive to whether the analysis accounted for observed NT-proBNP treatment effect heterogeneity. The cost-effectiveness of vericiguat was driven by the projected incremental life expectancy among patients in the lowest 3 quartiles of NT-proBNP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT02861534.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37671551/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37671551</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063602>10.1161/CIRCULATIONAHA.122.063602</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37671551</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Derek S Chew</dc:creator>
<dc:creator>Yanhong Li</dc:creator>
<dc:creator>Robert Bigelow</dc:creator>
<dc:creator>Patricia A Cowper</dc:creator>
<dc:creator>Kevin J Anstrom</dc:creator>
<dc:creator>Melanie R Daniels</dc:creator>
<dc:creator>Linda Davidson-Ray</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Christopher M O'Connor</dc:creator>
<dc:creator>Paul W Armstrong</dc:creator>
<dc:creator>Daniel B Mark</dc:creator>
<dc:creator>VICTORIA Study Group</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37671551</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.063602</dc:identifier>
</item>
<item>
<title>Reducing radiation to the heart in breast cancer: is that all that matters?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37670408/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 6:ehad528. doi: 10.1093/eurheartj/ehad528. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37670408/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37670408</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad528>10.1093/eurheartj/ehad528</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37670408</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Marianne Aznar</dc:creator>
<dc:creator>Anju Nohria</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Reducing radiation to the heart in breast cancer: is that all that matters?</dc:title>
<dc:identifier>pmid:37670408</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad528</dc:identifier>
</item>
<item>
<title>Artificial intelligence and innovation of clinical care: the need for evidence in the real world</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37670406/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 6:ehad553. doi: 10.1093/eurheartj/ehad553. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37670406/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37670406</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad553>10.1093/eurheartj/ehad553</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37670406</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Andrew J Fletcher</dc:creator>
<dc:creator>Casey L Johnson</dc:creator>
<dc:creator>Paul Leeson</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence and innovation of clinical care: the need for evidence in the real world</dc:title>
<dc:identifier>pmid:37670406</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad553</dc:identifier>
</item>
<item>
<title>The stroke enigma: decoding the sex risk factor in atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37670405/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 6:ehad531. doi: 10.1093/eurheartj/ehad531. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37670405/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37670405</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad531>10.1093/eurheartj/ehad531</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37670405</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Melissa E Middeldorp</dc:creator>
<dc:creator>Roopinder K Sandhu</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The stroke enigma: decoding the sex risk factor in atrial fibrillation</dc:title>
<dc:identifier>pmid:37670405</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad531</dc:identifier>
</item>
<item>
<title>Remote heart failure management guided by pulmonary artery pressure home monitoring: rewriting the future?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37670404/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230907021034&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 6:ehad525. doi: 10.1093/eurheartj/ehad525. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37670404/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230907021034&v=2.17.9.post6+86293ac">37670404</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad525>10.1093/eurheartj/ehad525</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37670404</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Christiane E Angermann</dc:creator>
<dc:creator>Georg Ertl</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Remote heart failure management guided by pulmonary artery pressure home monitoring: rewriting the future?</dc:title>
<dc:identifier>pmid:37670404</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad525</dc:identifier>
</item>





























</channel>
</rss>